New guidelines from the American College of Cardiology and American Heart Association update best practices for managing peripheral artery disease (PAD). The comprehensive clinical guidelines synopsis ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

According to the National Heart, Lung, and Blood Institute, nearly 10 million people aged 40 and older have Peripheral Artery ...

Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless ...

A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 ...

Regular walking emerges as a potent strategy against dementia and heart disease, especially for older adults in India, where ...

Among patients with moderate peripheral artery disease, GLP-1 use was associated with reduced risk for cardiovascular and ...

Code Orange Ozone Forecast for Thursday... The Shelby County Health Department has issued a Code Orange Ozone Forecast ...

Global Peripheral Artery Disease Market is valued at approximately USD 4.5 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.7% over the forecast period 2024-2032.

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Individuals with MASLD with a lean vs nonlean body type have increased mortality and cardiovascular disease, among other outcomes.